摘要
目的：了解培哚普利对充血性心衰（ＣＨＦ）的治疗作用和可能的机理。方法：将４０例ＣＨＦ患者随机分为对照组（ｎ＝１７），用利尿剂和洋地黄治疗。培哚普利治疗组（ｎ＝２３），在前者基础上加服培哚普利（２ｍｇ／ｄ～４ｍｇ／ｄ），治疗约一个月。观察治疗前后症状、ＮＹＨＡ、心功能和心脏结构，心钠素（ＡＮＦ）、内皮素（ＥＴ）及肾素－血管紧张素－醛固酮系统（ＲＡＡＳ）各成分的改变情况。结果：与常规治疗组相比培哚普利可以明显改善患者心功能，血流动力学状况，抑制心肌重构发生发展，血液ＲＡＡＳ受到抑制，ＡＮＦ合成和ＥＴ释放减少。结论：认为培哚普利可以改善心衰患者的心功能，减轻心脏负荷，阻断重构的发生。其治疗机理复杂，除抑制ＲＡＡＳ之外，可能与ＡＮＦ合成和ＥＴ分泌减少有关。
Objective: To investigate the therapeutic effects of perindopril on congestive heart failure (CHF) and its possible mechanism. Methods: 40 patients (20 males, 20 females) with the age ranging from 21 to77 years old(mean=51.47) were randomized into the control group (n=17) treated with digitalis and diuretics and the treatment group (n=23) treated with perindopril, digitalis and diuretics. Then the changes of the following indices were observed: 1)NYHA class; 2)hemodynamics and cardiac performance such as FS, EF, CI, CO and SV; 3)VST, LVID, LVPWT and LV mass; 4)plasma ANF, ANGII, Ald, ET, ACE and PRA. Results: In the treatment group, it was found that: 1)NYHA class was ameliorated; 2)the cardiac performance and hemodynamics were improved; 3)the blood RAAS was inhibited; 4)the synthesis of ANF and discharge of ET were significantly decreased. Conclusion: Perindopril is an effective agent in the treatment of CHF. Its mechanism might be to decrease the synthesis of ANF and discharge of ET besides inhibiting RAAS
出处
《第三军医大学学报》
CAS
CSCD
北大核心
1997年第3期257-260,共4页
Journal of Third Military Medical University
关键词
培哚普利
充血性心力衰竭
药物疗法
perindopril
congestive heart failure (CHF)
reninangiotensinasdsterone system (RAAS)
